Can West Pharmaceutical’s (WST) Extended Supply Deal Reveal Insights Into Its Margin Strategy?

• On August 20, 2025, scPharmaceuticals Inc. announced an amendment to its supply agreement with West Pharmaceutical Services, extending the term through December 31, 2027, and clarifying termination cost obligations for both parties.
• This update highlights both the ongoing relationship around West's SmartDose drug delivery system and the company's continued role as a key supplier in the injectable drug delivery market.
• We'll explore how the supply agreement extension and terms may impact West Pharmaceutical Services' long-term growth outlook and margins.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

West Pharmaceutical Services Investment Narrative Recap

To be a shareholder in West Pharmaceutical Services, you need to believe in the company’s ability to maintain its market position in specialty drug delivery while capitalizing on emerging therapeutic trends like GLP-1 demand and automation in high-value product lines. The recent extension of the supply agreement for the SmartDose system strengthens its position as a key supplier but does not materially shift the core short-term catalyst of scaling higher-margin businesses; the biggest risk remains margin pressure from lower pricing and cost uncertainties.

Of the recent announcements, the agreement extension with scPharmaceuticals stands out for its relevance; it provides near-term revenue stability for West’s SmartDose platform, aligning with ongoing efforts to offset variability in contract manufacturing and support growth in high-value segments. While contractual visibility is a plus, margin improvement will still depend on the transition to automated production lines and sustained pricing power in its core products.

In contrast, investors should keep a close eye on how margin pressures could affect earnings if pricing trends or cost headwinds continue to build…

Read the full narrative on West Pharmaceutical Services (it's free!)

West Pharmaceutical Services' outlook anticipates $3.6 billion in revenue and $675.2 million in earnings by 2028. This targets a 6.5% annual revenue growth rate and a $187.5 million increase in earnings from the current $487.7 million.

Uncover how West Pharmaceutical Services' forecasts yield a $316.36 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Five individual fair value estimates from the Simply Wall St Community place the shares between US$127 and US$316, highlighting the wide range of expectations. You can compare these outlooks with the ongoing challenge of cost control and pressure on operating margins to better understand how market uncertainty may shape future returns.

Explore 5 other fair value estimates on West Pharmaceutical Services - why the stock might be worth as much as 28% more than the current price!

Build Your Own West Pharmaceutical Services Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your West Pharmaceutical Services research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free West Pharmaceutical Services research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate West Pharmaceutical Services' overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com